article thumbnail

Case study: NCI’s Molecular Targets Platform

The Open Targets Blog

[ Deanne Taylor ] The purpose of the project was to deliver harmonized genomic information to support therapeutic discovery in pediatric cancer. The Open Targets delivers easy-to-navigate aggregated information and evidence linking therapies, genes, and diseases.

article thumbnail

Terra is now generally available on Microsoft Azure

Broad Institute

Through Terra, researchers can gain access to genomics and other data modalities used for biomedical research, as well as run state-of-the-art workflows developed by Broad and wider bioinformatics community. For more information on Terra on Azure, please visit Terra.Bio.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

Prof Rory Johnson is an Associate Professor at University College Dublin, where his research focusses on uncovering the roles of long noncoding RNAs (lncRNAs) in human health and disease using an interdisciplinary combination of bioinformatic and experimental methods.

RNA 59
article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

Omics data, including pharmacogenomics data from 3D-TGAs, provide us with unique information about the molecular mechanisms of disease biology and drug response. Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

article thumbnail

Case study: Extracting tidy data from Open Targets Genetics with Otargen

The Open Targets Blog

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. Their work was recently published in Bioinformatics. We chat with him about otargen, and the importance of sharing open-source resources within the bioinformatics community.

article thumbnail

Unlocking the potential of natural products in drug discovery

Drug Target Review

The greater the MS/MS coverage, the more structural information is acquired. Structural information is then combined with biological assays to identify the compounds that have the most potential for therapeutic development. References Newman DJ, Cragg GM.

article thumbnail

Vitamin A and its role in psychiatric and other disorders

Drug Target Review

Murray has used his expertise in bioinformatics to establish an internationally recognised laboratory specialising in complex trait genomics. He is a leader in genetically informed precision medicine and is developing transformative approaches to address the problem of heterogeneity in the treatment of complex disorders.